SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) experienced a 3.9% decline in its stock price on Monday, continuing a downward trend that saw an 8.3% drop the previous Friday. The shares hit an intraday low of $9.60 before recovering to $10.88 by early afternoon trading. This movement contrasted with the broader biotechnology sector, as the State Street SPDR S&P Biotech ETF (NYSEARCA: XBI) rose approximately 0.8% during the same period, indicating that the weakness was company-specific rather than sector-wide.
Dilution and Valuation Concerns
The decline appears to be driven by concerns over shareholder dilution. The real-time market feed displayed a market value of $1.88 billion based on a share price of $10.88, which corresponds to 172.5 million shares outstanding. However, this figure aligns with SELLAS' weighted average share count from the first quarter, not the most recent total. On June 2, the company revealed that the number of outstanding shares had risen to 196.6 million, largely due to warrant exercises. Based on Monday's share price, this implies a provisional equity valuation of $2.14 billion, representing a $263 million or 14% premium over the live-feed market value.
Shares have increased by 28.4% since the end of last year, but the dilution has been significant. The outstanding share count grew from 153.1 million as of December 31 to 196.6 million by June 2, driven by warrant exercises that generated $72.8 million in proceeds by May. This amount was 8.2 times greater than the operating cash used during the first quarter, providing the company with greater financial flexibility but at the cost of existing shareholders' equity.
REGAL Trial Progress
The upcoming formal catalyst for SELLAS is the final analysis of its Phase 3 REGAL study, which is evaluating galinpepimut-S (GPS) against standard therapy in patients with acute myeloid leukemia following a second complete remission. The main endpoint is overall survival. As of the latest update, 78 death events have been recorded, just two away from the threshold of 80 required to trigger the final analysis. An independent committee reviewed unblinded data after 60 events and recommended the trial proceed without modifications, citing no safety concerns. The company remains blinded to results by treatment group, meaning the rate of combined deaths does not reveal whether survival is being affected by GPS or the control group.
In May, Chief Executive Angelos Stergiou described the results stemming from the 80th event as "an important milestone for the Company." The event will prompt database locking, a blinded review, statistical evaluation, and eventual unblinding, with initial top-line data released afterward.
Cash Position and Other Programs
SELLAS reported $107.1 million in cash as of March 31. Including warrant proceeds from April and May, the total rises to $135.8 million before any spending in the second quarter. With an equity value of approximately $2.14 billion, nearly 94% of that valuation exceeds this gross cash amount, meaning the company's valuation is heavily dependent on the success of its pipeline. The pro forma cash-adjusted equity value stands at roughly $2.00 billion, with gross cash making up about 6.3% of the total valuation.
Investors also have access to a second AML program through SLS009, with top-line results from an 80-patient Phase 2 first-line study anticipated in the fourth quarter. Funding concerns have eased but persist; in May, SELLAS indicated it had sufficient resources to support its planned activities for at least 12 months. However, the company maintains a $150 million at-the-market program that poses additional dilution risk to shareholders.
Risks and Outlook
The risks are concentrated on the REGAL endpoint. If the trial does not succeed, a significant portion of the $2.00 billion cash-adjusted valuation could be at risk. Other potential headwinds include increased expenses, changes to the schedule of events, and the possibility of additional equity offerings. For investors, the 80th-event notice merely signals the beginning; the critical data will come from the overall-survival outcome when unblinded.
